The objective of this Core is to provide state-of-the-art mass spectrometry-based proteomic capabilities to MUSC DDRC investigators. It provides not only mass spectrometry to allow the discovery of the effects of drugs/ligands, genetic alterations, and disease on changes in protein expression, protein interactions, and post-translational modifications, but in a highly unique and innovative component, it provided MS-imaging.
This Core has extensive experience in investigation of post-translational modifications and thus provides investigators the opportunity to investigate responses to ligand stimulation by examining protein function, half-life, and localization. To provide the services of this DDRC Core in a cost-effective manner, existing MUSC Mass Spectrometry Facility resources (including an extensive array of instrumentation) are leveraged. Unique for the DDRC, this Core also has expertise and an innovative track record in mass spectrometry based imaging of tissue in situ. As alterations in extracellular matrix proteins are a hallmark of many digestive diseases, this attribute is highly relevant to the community. Lastly, through our expertise in developing mass spectrometry based imaging, we provide MS-imaging technologies for the analysis of metabolites, lipids, glycolipid and glycans in tissue.